231 related articles for article (PubMed ID: 22553997)
21. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
22. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Roston TM; Cunningham TC; Sanatani S
Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
[TBL] [Abstract][Full Text] [Related]
23. Electrical storm of monomorphic ventricular tachycardia after a cardiac-resynchronization-therapy-defibrillator upgrade.
Kantharia BK; Patel JA; Nagra BS; Ledley GS
Europace; 2006 Aug; 8(8):625-8. PubMed ID: 16772367
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Vaksmann G; Klug D
Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
[TBL] [Abstract][Full Text] [Related]
25. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
[TBL] [Abstract][Full Text] [Related]
26. Initiation of ventricular tachycardia by interruption of pacemaker-mediated tachycardia in a patient with a dual-chamber implantable cardioverter defibrillator.
Van Gelder BM; Meijer A; Dekker LR; Bracke FA
Pacing Clin Electrophysiol; 2009 Sep; 32(9):1227-30. PubMed ID: 19719503
[TBL] [Abstract][Full Text] [Related]
27. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Claudio B; Alice M; Daniel S
Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
[TBL] [Abstract][Full Text] [Related]
28. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2020 May; 43(5):527-533. PubMed ID: 32259298
[TBL] [Abstract][Full Text] [Related]
29. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy.
Kazemian P; Gollob MH; Pantano A; Oudit GY
Can J Cardiol; 2011; 27(6):870.e7-10. PubMed ID: 21652165
[TBL] [Abstract][Full Text] [Related]
30. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
Imberti JF; Underwood K; Mazzanti A; Priori SG
Heart Lung Circ; 2016 Aug; 25(8):777-83. PubMed ID: 26948768
[TBL] [Abstract][Full Text] [Related]
31. [Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation].
Przybylski A; Derejko P; Iwanek M; Urbanek P; Kepski R; Grzybowski J; Chojnowska L; Szumowski Ł; Szwed H; Walczak F
Kardiol Pol; 2006 Jul; 64(7):758-62. PubMed ID: 16886137
[TBL] [Abstract][Full Text] [Related]
32. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
34. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: an international multicenter prospective study.
Sadoul N; Mletzko R; Anselme F; Bowes R; Schöls W; Kouakam C; Casteigneau G; Luise R; Iscolo N; Aliot E;
Circulation; 2005 Aug; 112(7):946-53. PubMed ID: 16103252
[TBL] [Abstract][Full Text] [Related]
35. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
Watanabe H; Chopra N; Laver D; Hwang HS; Davies SS; Roach DE; Duff HJ; Roden DM; Wilde AA; Knollmann BC
Nat Med; 2009 Apr; 15(4):380-3. PubMed ID: 19330009
[TBL] [Abstract][Full Text] [Related]
36. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia.
Marai I; Khoury A; Suleiman M; Gepstein L; Blich M; Lorber A; Boulos M
Am J Cardiol; 2012 Jul; 110(1):72-6. PubMed ID: 22481011
[TBL] [Abstract][Full Text] [Related]
37. Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia.
Aksu T; Güler TE; Özcan KS; Bozyel S; Yalın K
Turk Kardiyol Dern Ars; 2017 Jul; 45(5):441-449. PubMed ID: 28694398
[TBL] [Abstract][Full Text] [Related]
38. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.
Pellizzón OA; Kalaizich L; Ptácek LJ; Tristani-Firouzi M; Gonzalez MD
J Cardiovasc Electrophysiol; 2008 Jan; 19(1):95-7. PubMed ID: 17655675
[TBL] [Abstract][Full Text] [Related]
39. Death due to an implantable cardioverter defibrillator.
Messali A; Thomas O; Chauvin M; Coumel P; Leenhardt A
J Cardiovasc Electrophysiol; 2004 Aug; 15(8):953-6. PubMed ID: 15333095
[TBL] [Abstract][Full Text] [Related]
40. A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
Mantziari L; Vassilikos V; Anastasakis A; Kotsaka X; Paraskevaidis S; Styliadis IH; Luria D
Ann Noninvasive Electrocardiol; 2013 Nov; 18(6):571-6. PubMed ID: 24147812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
